Category Archives: Muscular Dystrophy Treatment

SMT C1100 For Duchenne Muscular Dystrophy Moves To Human Testing

MDA Supported Reformulation of Utrophin-Boosting Compound Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , | Comments Off

Local Child Battles Muscular Dystrophy

Shannon Ballard sballard@kjct8.com Copyright 2010 KJCT. All rights reserved Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , | Comments Off

Myomatrix 2012 conference to take place from April 22-24

The nation’s leading scientists and clinicians exploring treatment breakthroughs for congenital muscular dystrophy will convene April 22-24 on the campus of the University of Nevada, Reno, where research by Dean Burkin has led to a potential therapy. At the Myomatrix 2012 conference, experts will share their latest data and findings – both published and soon to be published research – seeking ways to build on recent progress. Burkin, a pharmacological researcher and faculty member at the University of Nevada School of Medicine, will present his work on laminin-111, a naturally occurring protein showing promise as a therapy for muscular dystrophy Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , , , | Comments Off

Nature Publishes Work Utilizing N-Gene's Core Technology to Advance the Treatment of Duchenne Muscular Dystrophy

NEW YORK, April 19, 2012 /PRNewswire/ –N-Gene Research Laboratories, Inc. (“N-Gene”), today announces that Australian scientists in close cooperation with N-Gene have shown that BGP-15, a heat shock protein inducer, may be a novel therapy for treating the deadly, rare disease, Duchenne Muscular Dystrophy (DMD), as recently reported in the journal Nature Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , | Comments Off

Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno

Public release date: 18-Apr-2012 [ | E-mail | Share ] Contact: Mike Wolterbeek mwolterbeek@unr.edu University of Nevada, Reno RENO, Nev. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , | Comments Off

U.S. Stock Futures Little Changed Before Factory Report

By Namitha Jagadeesh – Mon Apr 02 12:06:26 GMT 2012 U.S. stock-index futures declined as investors awaited a report that may show manufacturing expanded in the worlds biggest economy. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , | Comments Off

AVI BioPharma Announces Eteplirsen Meets Primary Endpoint, Demonstrating a Significant Increase in Dystrophin at 24 …

SOURCE: AVI BioPharma, Inc. BOTHELL, WA–(Marketwire – Apr 2, 2012) – AVI BioPharma, Inc. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , | Comments Off

AVI BioPharma's Eteplirsen Meets PrimaryEndpoint For Duchenne Muscular Dystrophy

(RTTNews.com) – AVI BioPharma Inc. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , | Comments Off

Drug for rare disease may lift AVI BioPharma shares: Barron's

NEW YORK (Reuters) – AVI BioPharma Inc’s shares could get a boost if its drug targeting treatment for a rare fatal form of muscular dystrophy proves to be effective in clinical drug trials, according to an article in the April 2 edition of Barron’s. Clinical trial results for AVI’s drug Eteplirsen were expected later this month, Barron’s said Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , , , , , , | Comments Off

AVI BioPharma Announces Conference Call and Webcast on Monday, April 2, 2012, to Discuss Top-Line Data Results From …

SOURCE: AVI BioPharma, Inc. BOTHELL, WA–(Marketwire – Mar 30, 2012) – AVI BioPharma, Inc. Continue reading

Posted in Muscular Dystrophy Treatment | Tagged , , , , , , , | Comments Off